mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.

导出 OA

翻译打印收藏纠错

作者： Sean T,Bailey ^[1] ; Bing,Zhou ^[2] ; Jeffrey S,Damrauer ^[1] ; Bhavani,Krishnan ^[2] ; Harper L,Wilson ^[2] ; Aleisha M,Smith ^[2] ; Mingqing,Li ^[2] ; Jen Jen,Yeh ^[3] ; William Y,Kim ^[4]

作者单位： Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. ^[1] Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. ^[2] Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. ^[3] Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. ^[4]